OBJECTIVE: Although depression is a risk and prognostic factor for cardiovascular disease (CVD), depression trials involving cardiac patients have not observed the anticipated cardiovascular benefits. To test our hypothesis that depression treatment delivered before clinical CVD onset reduces risk of CVD events, we conducted an 8-year follow-up study of the Indiana sites of the Improving Mood-Promoting Access to Collaborative Treatment (IMPACT) randomized controlled trial. METHODS:Participants were 235 primary care patients 60 years or older with major depression or dysthymia who were randomized to a 12-monthcollaborative care program involving antidepressants and psychotherapy (85 without and 35 with baseline CVD) or usual care (83 without and 32 with baseline CVD). Hard CVD events (fatal/nonfatal) were identified using electronic medical record and Medicare/Medicaid data. RESULTS: A total of 119 patients (51%) had a hard CVD event. As hypothesized, the treatment × baseline CVD interaction was significant (p = .021). IMPACT patients without baseline CVD had a 48% lower risk of an event than did usual care patients (28% versus 47%, hazard ratio = 0.52, 95% confidence interval = 0.31-0.86). The number needed to treat to prevent one event for 5 years was 6.1. The likelihood of an event did not differ between IMPACT and usual care patients with baseline CVD (86% versus 81%, hazard ratio = 1.19, 95% confidence interval, 0.70-2.03). CONCLUSIONS: Collaborative depression care delivered before CVD onset halved the excess risk of hard CVD events among older, depressed patients. Our findings raise the possibility that the IMPACT intervention could be used as a CVD primary prevention strategy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01561105.
RCT Entities:
OBJECTIVE: Although depression is a risk and prognostic factor for cardiovascular disease (CVD), depression trials involving cardiac patients have not observed the anticipated cardiovascular benefits. To test our hypothesis that depression treatment delivered before clinical CVD onset reduces risk of CVD events, we conducted an 8-year follow-up study of the Indiana sites of the Improving Mood-Promoting Access to Collaborative Treatment (IMPACT) randomized controlled trial. METHODS:Participants were 235 primary care patients 60 years or older with major depression or dysthymia who were randomized to a 12-month collaborative care program involving antidepressants and psychotherapy (85 without and 35 with baseline CVD) or usual care (83 without and 32 with baseline CVD). Hard CVD events (fatal/nonfatal) were identified using electronic medical record and Medicare/Medicaid data. RESULTS: A total of 119 patients (51%) had a hard CVD event. As hypothesized, the treatment × baseline CVD interaction was significant (p = .021). IMPACT patients without baseline CVD had a 48% lower risk of an event than did usual care patients (28% versus 47%, hazard ratio = 0.52, 95% confidence interval = 0.31-0.86). The number needed to treat to prevent one event for 5 years was 6.1. The likelihood of an event did not differ between IMPACT and usual care patients with baseline CVD (86% versus 81%, hazard ratio = 1.19, 95% confidence interval, 0.70-2.03). CONCLUSIONS: Collaborative depression care delivered before CVD onset halved the excess risk of hard CVD events among older, depressedpatients. Our findings raise the possibility that the IMPACT intervention could be used as a CVD primary prevention strategy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01561105.
Authors: Denise C Cooper; Lianne M Tomfohr; Milos S Milic; Loki Natarajan; Wayne A Bardwell; Michael G Ziegler; Joel E Dimsdale Journal: Psychosom Med Date: 2011-06-02 Impact factor: 4.312
Authors: J Unützer; W Katon; J W Williams; C M Callahan; L Harpole; E M Hunkeler; M Hoffing; P Arean; M T Hegel; M Schoenbaum; S M Oishi; C A Langston Journal: Med Care Date: 2001-08 Impact factor: 2.983
Authors: K Kroenke; S L West; R Swindle; A Gilsenan; G J Eckert; R Dolor; P Stang; X H Zhou; R Hays; M Weinberger Journal: JAMA Date: 2001-12-19 Impact factor: 56.272
Authors: Alexander H Glassman; Christopher M O'Connor; Robert M Califf; Karl Swedberg; Peter Schwartz; J Thomas Bigger; K Ranga Rama Krishnan; Louis T van Zyl; J Robert Swenson; Mitchell S Finkel; Charles Landau; Peter A Shapiro; Carl J Pepine; Jack Mardekian; Wilma M Harrison; David Barton; Michael Mclvor Journal: JAMA Date: 2002-08-14 Impact factor: 56.272
Authors: Karina W Davidson; J Thomas Bigger; Matthew M Burg; Robert M Carney; William F Chaplin; Susan Czajkowski; Ellen Dornelas; Joan Duer-Hefele; Nancy Frasure-Smith; Kenneth E Freedland; Donald C Haas; Allan S Jaffe; Joseph A Ladapo; Francois Lespérance; Vivian Medina; Jonathan D Newman; Gabrielle A Osorio; Faith Parsons; Joseph E Schwartz; Jonathan A Shaffer; Peter A Shapiro; David S Sheps; Viola Vaccarino; William Whang; Siqin Ye Journal: JAMA Intern Med Date: 2013-06-10 Impact factor: 21.873
Authors: Kimberly A Mc Cord; Hannah Ewald; Aviv Ladanie; Matthias Briel; Benjamin Speich; Heiner C Bucher; Lars G Hemkens Journal: CMAJ Open Date: 2019-02-03
Authors: Beth Waitzfelder; Christine Stewart; Karen J Coleman; Rebecca Rossom; Brian K Ahmedani; Arne Beck; John E Zeber; Yihe G Daida; Connie Trinacty; Samuel Hubley; Gregory E Simon Journal: J Gen Intern Med Date: 2018-02-08 Impact factor: 5.128
Authors: Jesse C Stewart; Misty A W Hawkins; Tasneem Khambaty; Anthony J Perkins; Christopher M Callahan Journal: Psychosom Med Date: 2016-06 Impact factor: 4.312